Old West Investment Management LLC Invests $5.05 Million in Thermo Fisher Scientific Inc. $TMO

Key Points

• Old West Investment Management purchased 10,083 Thermo Fisher Scientific shares worth approximately $5.05 million in the second quarter. Institutional investors collectively own 89.23% of the company.
• Analysts maintain a generally bullish outlook, with Thermo Fisher receiving a “Moderate Buy” consensus rating and an average price target of $619.41.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in earnings per share and $11.99 billion in revenue, while revenue rose 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share.

Old West Investment Management LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,083 shares of the medical research company's stock, valued at approximately $5,055,000.

Several other institutional investors also recently bought and sold shares of the business. N.E.W. Advisory Services LLC acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth $123,000. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $126,623,000. HBK Sorce Advisory LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth $4,072,000. German American Bancorp Inc. acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $4,920,000. Finally, Nippon Life Global Investors Americas Inc. purchased a new position in Thermo Fisher Scientific in the second quarter valued at about $7,331,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Robert W. Baird decreased their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research report on Friday, April 24th. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Barclays increased their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. Finally, Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $586.12, for a total transaction of $2,700,840.96. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

TMO opened at $586.62 on Tuesday. The company has a market capitalization of $216.90 billion, a P/E ratio of 31.56, a PEG ratio of 2.39 and a beta of 0.84. The company has a 50-day moving average of $531.72 and a 200-day moving average of $508.48. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period last year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source